Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries

Bone Marrow Transplantation

Volumn 22, Issue 2, 1998, Pages 117-124

  Clarke, E ^a   Potter, M N ^b,d   Hale, G ^c   Waldmann, H ^c   Lankester, A ^a   Cornish, J M ^b   Steward, C G ^b   Marks, D I ^b   Oakhill, A ^b   Pamphilon, D H ^a,b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Campath 1M; Immunoselection; Sequential T cell depletion

Indexed keywords

ALEMTUZUMAB; CD2 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; COMPLEMENT; CYCLOSPORIN A; HLA ANTIGEN; METHOTREXATE;

ANTIBODY AFFINITY; ARTICLE; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; BURST FORMING UNIT E; CELL SELECTION; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 17644442155     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701296     Document Type: Article

References (38)

1. Chen CS, Sorensen PH. Domer PH et al. Molecular rearrangement on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386-2393.
2. Slovak ML, Kopecky KJ, Wolman SR et al. Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group Study (SWOG 8612). Leukemia Res 1995; 19: 381-388.
3. Ebell W, Reiter A, Riehm H. Chemotherapy versus bone marrow transplantation in childhood acute lymphoblastic leukaemia. BFM study group. Eur J Pediair 1992; 151: s50-s54.
4. Petersdorf EW, Longton GM, Anasetti C et al Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997; 89: 1818-1823.
5. Anasetti C. Howe C, Petersdorf EW el al. Marrow transplants from HLA-matched unrelated donors: an NMPD update and the Seattle experience. Bone Marrow Transplant 1994; 13: 693-695.
6. A versa F, Tabilio A Velardi A et al. Successful engraftment of T-cell depleted haploidentical 'three loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
7. Waldmann H, Polliak A, Hale G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2: 483-486.
8. Levinsky RJ. Recent advances in bone marrow transplantation. Clin Immunol Immunopathol 1989; 50: S124-S132.
9. Mackinnon SS, Hows JM. Goldman JM et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol 1990; 18: 421-425.
10. Prentice HG, Sekhar M, Popat U et al. Donor leucocyte infusions for relapsed acute leukemia post BMT. Blood 1995; 86; 566 (Abstr.).
11. Bachar-Lustis E, Rachamim N. Li HW et al. Mesadose of T- cell depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nature Med 1996; 1: 1268-1273.
12. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for the treatment of recurrent chronic myelogen- ous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
13. Szer J, Grigg AP, Phillips GL et al. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 11: 109-111.
14. Prentice HG, Sekhar M, Deane M et al. The immunotherapy of acute myeloblastic leukemia; from allogeneic BMT to gene transfer. Blood 1995; 86: 617 (Abstr.).
15. Bader P. Holle W, Klingebiel T et al. Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 1997; 697-702.
16. Barren AJ, Mavroudis D, Molldrem J er al. Optimizing the dose and timing of lymphocyte add-back in T-cell depleted BMT between HLA-identical siblings. Blood 1996; 88: 460 (Abstr.).
17. Clarke E, Potter MN, Oakhill A et al, A laboratory comparison of T-cell depletion by CD34+ cell immunoaffinity selection and in vitro Carnpau-lM treatment: clinical implications for bone marrow transplantation and donor leukocyte therapy. Bone Marrow Transplant 1997; 33: 599-605.
18. Urbano Ispizua A. Rozman C, Martínez C et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 1997; 89: 3967-3973.
19. Link H, Arseniev L, Bähre O el al. Transplantation of allogeneic CD34+ blood cells. Blood 1996; 87: 4903-4909.
20. Bensinger WI, Buckner CD, Shannon-Dorcy K et al. Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients with advanced hematologic malignancy. Blood 1996; 88: 4132-4138.
21. + selected and Campath treated bone marrow (BM): evaluation of T-cell depletion and progenitor proliferative potential. Blood 1996; 88: 254 (Abstr.).
22. Oakhill A, Pamphilon DH. Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haemmol 1996: 94: 574-577.
23. Gengozian N. Carlson DE. Allen EM. Transplantation of allogeneic and xenogeneic (rat) marrow in irradiated mice as affected by radiation exposure rates. Transplantation 1969; 7: 259-273.
24. Hale G. Waldmann H for CAMPATH Users. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother 1994; 3: 15-31.
25. Berenson RJ, Bensinger WI. Kalamasz D. Positive selection of viable cell populations using avidin-biotin immunoadsorption. J Immunol Meth 1986; 91: 11-19.
26. McNiece IK, Langley KE. Zsebo KM. Recombinant human stem cell factor synergises with GM-CSF. G-CSF. IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991: 19: 226-231.
27. Kernan NA, Flomenberg N. Collins NH er al. Quantitation of T-lymphocytes in human bone marrow by a limiting dilution assay. Transplantation 1985; 40: 317-322.
28. Esperou H, Marolleau JP, Rocha V et al. Enriched CD34+ bone marrow cells with Isolex 300 (Baxter TM) devices reduce severe graft-versus-host disease (GVHD) in allogeneic bone marrow transplantation with unrelated donor (UD-BMT). Blood 1997; 90: 111 (Abstr.).
29. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
30. Laport GF, Bensinger W, Daugherty CK et al. A pilot study of allogeneic CD34+ peripheral blood stem cell transplantation (PBSCT) using mismatched related donors for patients with advanced hematologic malignancies. Blood 1997; 90: 110 (Abstr.).
31. Kernan NA, Collins NH, Juliano L et al. Clonable T-lympho-cytes in T-cell depleted bone marrow transplants correlates with development of graft-versus-host disease. Blood 1986: 86: 770-773.
32. Simon M, Bartram CR. Friedrich W et al. Fatal B-cell lymphoproliferative syndrome in allogeneic marrow allograft recipients. A clinical immunobiological and pathological study. Virchow Arch B Cell Pathol 1991; 60: 307-.319.
33. Hale G, Waldrnann H for CAMPATH Users. Risks of developing EBV-related lymphoproliferative disorders following T-cell depleted marrow transplants. (Submitted).
34. Mavroudis D. Read E, Cottier-Fox M et al. CD34+ cell dose predicts survival, posttransplant morbidity and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
35. Collins P, Watts M. Brocklesby M et al. Successful engraftment of haploidentical stem cell transplant for familial haemophagocytic lymphohistocytosis using both bone marrow and peripheral blood stem cells. Br J Haematol 1997; 96: 644-646.
36. Knechtli C, Goulden N, Garland R er al. Analysis of minimal residual disease predicts relapse after T-depleted BMT for childhood ALL. Bone Marrow Transplant 1996; 17: S100 (Abstr.).
37. Bertolini F, Thomas T, Battaglia M et al. A new 'two step' procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. Bone Marrow Transplant 1997; 19: 615-619.
38. Gilleece MH, Dexter TM, Effects of Campath-lH antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807-812.